Table 2.
Patient characteristics according to high or low PCAT attenuation.
| High PCAT attenuation (≥ −72.5 HU) | Low PCAT attenuation (< −72.5 HU) | P value | |
| N | 78 | 78 | |
| Age, yrs | 62 ± 13 | 62 ± 11 | .951 |
| Males | 64 (82) | 52 (67) | .028 |
| Body mass index, kg/m2 | 26 ± 3 | 26 ± 4 | .951 |
| Hypertension | 29 (37) | 25 (32) | .501 |
| Diabetes mellitus | 42 (54) | 46 (59) | .518 |
| Dyslipidemia | 42 (54) | 46 (59) | .518 |
| Current smoker | 23 (30) | 21 (27) | .722 |
| ∗Obesity | 44 (56) | 38 (49) | .374 |
| β blocker | 13 (17) | 21 (27) | .121 |
| Calcium channel blocker | 27 (35) | 30 (39) | .618 |
| ACE-I or ARB | 37 (47) | 30 (39) | .258 |
| Statin | 24 (31) | 24 (31) | 1.000 |
| eGFR, ml/min/1.73 m2 | 71 ± 18 | 69 ± 15 | .536 |
| AST, IU/L | 27 ± 14 | 25 ± 9 | .282 |
| ALT, IU/L | 32 ± 18 | 28 ± 16 | .123 |
| Total cholesterol, mg/dL | 190 ± 35 | 194 ± 37 | .548 |
| LDL cholesterol, mg/dL | 116 ± 36 | 122 ± 32 | .287 |
| HDL cholesterol, mg/dL | 52 ± 11 | 53 ± 15 | .637 |
| Triglyceride, mg/dL | 129 (97–190) | 121 (98–189) | .792 |
| Hemoglobin A1c, % | 6.5 ± 1.2 | 6.2 ± 0.9 | .153 |
| hsCRP, mg/dL | 0.12 (0.06–0.22) | 0.11 (0.06–0.30) | .958 |
| High-risk plaques in LAD | 15 (19) | 8 (10) | .114 |
| Significant stenosis in LAD | 12 (15) | 14 (18) | .667 |
Data are presented as mean ± standard deviation, number (%), or median (25th–75th percentile).
∗
Obesity was defined as body mass index ≥ 25 kg/m2.
ACE-I = angiotensin-converting enzyme inhibitor, ALT = alanine aminotransferase, ARB = angiotensin receptor blockers, AST = aspartate aminotransferase, eGFR = estimated glomerular filtration rate, HDL = high-density lipoprotein, hsCRP = high-sensitivity C-reactive protein, HU = Hounsfield units, LAD = left anterior descending artery, LDL = low-density lipoprotein, NAFLD = non-alcoholic fatty liver disease, PCAT = pericoronary adipose tissue.